A nem alkoholos zsírmáj az átlagpopulációban 15–25%-ban fordul elő. Az alapvető eltérés a nem alkoholos zsírmáj és a metabolikus szindróma (2-es típusú diabetes mellitus, dyslipidaemia, hypertonia és obesitas) vonatkozásában az inzulinrezisztencia kialakulása. Lefolyása nem minden esetben jóindulatú folyamat, jól ismert a klinikai gyakorlatban idült májbetegséggé és cirrhosissá történő átalakulása, valamint együtt járhat hepatocellularis carcinoma kialakulásával is. A nem alkoholos zsírmáj emelkedett cardiovascularis kockázattal jár, és egyre inkább úgy tűnik, hogy nem pusztán az atherosclerosis markere, hanem korai mediátora is. Kezelése jelenleg a metabolikus szindrómába tartozó betegségek terápiájára irányul, amely a májműködést is javíthatja.
Musso, G., Gambino, R., Bo, S. és mtsai: Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? Diabet. Care, 2008, 31 , 562–568.
Bo S. , 'Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? ' (2008 ) 31 Diabet. Care : 562 -568 .
Eiszrich Á., Fehér J.: Gyermekkori zsírmáj. Orv. Hetil., 2007, 148 , 2461–2468.
Fehér J. , 'Gyermekkori zsírmáj ' (2007 ) 148 Orv. Hetil. : 2461 -2468 .
Day, C. P., James, O. F. W.: Steatohepatitis: a tale of two ‘hits’. Gastroenterology, 1998, 114 , 842–845.
James O. F. W. , 'Steatohepatitis: a tale of two ‘hits’ ' (1998 ) 114 Gastroenterology : 842 -845 .
Riley, P., O’Donohue, J., Crook, M.: A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J. Clin. Pathol, 2007, 60 , 1384–1391.
Crook M. , 'A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease ' (2007 ) 60 J. Clin. Pathol : 1384 -1391 .
Parekh, S., Anania, F. A.: Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease. Gastroenterology, 2007, 132 , 2191–2207.
Anania F. A. , 'Abnormal lipid and glucose metabolism in obesity: Implications for nonalcoholic fatty liver disease ' (2007 ) 132 Gastroenterology : 2191 -2207 .
Adams, L. A., Lindor, K. D.: Nonalcoholic fatty liver disease. Ann. Epidemiol., 2007, 17 , 863–869.
Lindor K. D. , 'Nonalcoholic fatty liver disease ' (2007 ) 17 Ann. Epidemiol. : 863 -869 .
Akbar, D. H., Kawther, A. H.: Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we dont’t know. Med. Sci. Monit., 2006, 12 , 23–26.
Kawther A. H. , 'Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we dont’t know ' (2006 ) 12 Med. Sci. Monit. : 23 -26 .
Targher, G., Bertolini, L., Padovani, R. és mtsai: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabet. Care, 2007, 30 , 1212–1218.
Padovani R. , 'Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients ' (2007 ) 30 Diabet. Care : 1212 -1218 .
Fraenkel E., Takács R., Hamvas J. és mtsai: A nem alkoholos zsírmáj és az epekövesség együttes előfordulásának megfigyelése. Orv. Hetil., 2007, 148 , 793–798.
Hamvas J. , 'A nem alkoholos zsírmáj és az epekövesség együttes előfordulásának megfigyelése ' (2007 ) 148 Orv. Hetil. : 793 -798 .
Bogdanova, K., Poczatkova, H., Uherkova, L. és mtsai: Non-alcoholic fatty liver disease (NAFLD) – a novel common aspect of the metabolic syndrome. Biomed. Pap. Med. Fac. Univ. Papacky Olomouc Czech. Repub., 2006, 150 , 101–104.
Uherkova L. , 'Non-alcoholic fatty liver disease (NAFLD) – a novel common aspect of the metabolic syndrome ' (2006 ) 150 Biomed. Pap. Med. Fac. Univ. Papacky Olomouc Czech. Repub. : 101 -104 .
Fehér J., Németh E., Lengyel G.: Non-alcoholic steatohepatitis (NASH) – is it a part of the metabolic syndrome? Arch. Med. Sci., 2005, 1 , 37–47.
Lengyel G. , 'Non-alcoholic steatohepatitis (NASH) – is it a part of the metabolic syndrome? ' (2005 ) 1 Arch. Med. Sci. : 37 -47 .
Tamura, S., Shimomura, I.: Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest., 2005, 115 , 1139–1142.
Shimomura I. , 'Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease ' (2005 ) 115 J. Clin. Invest. : 1139 -1142 .
Browning, J. D., Horton, J. D.: Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004, 114 , 147–152.
Horton J. D. , 'Molecular mediators of hepatic steatosis and liver injury ' (2004 ) 114 J. Clin. Invest. : 147 -152 .
Charlton, M., Sreekumar, R., Rasmussen, D. és mtsai: Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology, 2002, 35 , 898–904.
Rasmussen D. , 'Apolipoprotein synthesis in nonalcoholic steatohepatitis ' (2002 ) 35 Hepatology : 898 -904 .
Cummings, M. H., Watts, G. F., Umpleby, A. M. és mtsai: Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes, 1995, 44 , 1059–1065.
Umpleby A. M. , 'Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM ' (1995 ) 44 Diabetes : 1059 -1065 .
Gaemers, I. C., Groen, A. K.: New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol., 2006, 17 , 268–273.
Groen A. K. , 'New insights in the pathogenesis of non-alcoholic fatty liver disease ' (2006 ) 17 Curr. Opin. Lipidol. : 268 -273 .
Wolfrum, C., Asilmaz, E., Luca, E. és mtsai: Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature, 2004, 432 , 1027–1032.
Luca E. , 'Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes ' (2004 ) 432 Nature : 1027 -1032 .
Coppack, S. W.: Pro-inflammatory cytokines and adipose tissue. Proc. Nutr. Soc., 2001, 60 , 349–356.
Coppack S. W. , 'Pro-inflammatory cytokines and adipose tissue ' (2001 ) 60 Proc. Nutr. Soc. : 349 -356 .
Saxena, N. K., Ikeda, K., Rockey, D. C. és mtsai: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology, 2002, 35 , 762–771.
Rockey D. C. , 'Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice ' (2002 ) 35 Hepatology : 762 -771 .
Hui, J. M., Hodge, A., Farrell, G. C. és mtsai: Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology, 2004, 40 , 46–54.
Farrell G. C. , 'Beyond insulin resistance in NASH: TNF-α or adiponectin? ' (2004 ) 40 Hepatology : 46 -54 .
Pagano, C., Soardo, G., Pilon, C. és mtsai: Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J. Clin. Endocrinol. Metab., 2006, 91 , 1081–1086.
Pilon C. , 'Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 1081 -1086 .
Perseghin, G., Lattuada, G., De Cobelli, F. és mtsai: Serum resistin and hepatic fat content in non-diabetic individuals. J. Clin. Endocrinol. Metab., 2006, 91 , 5122–5125.
Cobelli F. , 'Serum resistin and hepatic fat content in non-diabetic individuals ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 5122 -5125 .
Graham, T. E., Yang, Q., Blüher, M. és mtsai: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med., 2006, 354 , 2552–2563.
Blüher M. , 'Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects ' (2006 ) 354 N. Engl. J. Med. : 2552 -2563 .
Neuschwander-Tetri, B. A.: Fatty liver and metabolic syndrome. Curr. Opin. Gastroenterol., 2007, 23 , 193–198.
Neuschwander-Tetri B. A. , 'Fatty liver and metabolic syndrome ' (2007 ) 23 Curr. Opin. Gastroenterol. : 193 -198 .
Fracanzani, A. L., Burdick, L., Rasselli, S. és mtsai: Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non alcoholic fatty liver disease: a case-control study. Hepatology, 2005, 42 , 610A–611A.
Rasselli S. , 'Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non alcoholic fatty liver disease: a case-control study ' (2005 ) 42 Hepatology : 610A -611A .
Villanova, N., Moscatiello, S., Ramilli, S. és mtsai: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology, 2005, 42 , 473–478.
Ramilli S. , 'Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease ' (2005 ) 42 Hepatology : 473 -478 .
Targher, G., Bertolini, L., Padovani, R. és mtsai: Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet. Med., 2006, 23 , 403–409.
Padovani R. , 'Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease ' (2006 ) 23 Diabet. Med. : 403 -409 .
Lin, Y. C., Lo, H. M., Chen, J. D.: Sonographic fatty liver, overweight and ischemic heart disease. World J. Gastroenterol., 2005, 11 , 4838–4842.
Chen J. D. , 'Sonographic fatty liver, overweight and ischemic heart disease ' (2005 ) 11 World J. Gastroenterol. : 4838 -4842 .
Wannamethee, G., Ebrahim, S., Shaper, A. G. és mtsai: Gamma-glutamyltransferase: determinants and association with mortality from ischaemic heart disease and all causes. Am. J. Epidemiol., 1995, 142 , 699–708.
Shaper A. G. , 'Gamma-glutamyltransferase: determinants and association with mortality from ischaemic heart disease and all causes ' (1995 ) 142 Am. J. Epidemiol. : 699 -708 .
Ruttmann, E., Brant, L. J., Concin, H. és mtsai: Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation, 2005, 112 , 2130–2137.
Concin H. , 'Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults ' (2005 ) 112 Circulation : 2130 -2137 .
Ioannou, G. N., Weiss, N. S., Boyko, E. J. és mtsai: Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology, 2006, 43 , 1145–1151.
Boyko E. J. , 'Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States ' (2006 ) 43 Hepatology : 1145 -1151 .
Fehér J., Lengyel G.: A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Med. Research, 2003, 31 , 537–551.
Lengyel G. , 'A new approach to drug therapy in non-alcoholic steatohepatitis (NASH) ' (2003 ) 31 J. Int. Med. Research : 537 -551 .
Watts, G. F., Gan, S. K.: Nutrition and metabolism: non-alcoholic fatty liver disease – pathogenesis, cardiovascular risk and therapy. Curr. Opin. Lipidol., 2008, 19 , 92–94.
Gan S. K. , 'Nutrition and metabolism: non-alcoholic fatty liver disease – pathogenesis, cardiovascular risk and therapy ' (2008 ) 19 Curr. Opin. Lipidol. : 92 -94 .
Bende J., Csiszár M., Ursu M.: Modern sebészi lehetőségek a nagyfokú elhízás kezelésében. Orv. Hetil., 2003, 144 , 2459–2463.
Ursu M. , 'Modern sebészi lehetőségek a nagyfokú elhízás kezelésében ' (2003 ) 144 Orv. Hetil. : 2459 -2463 .
De Alwis, N. M. W., Day, C. P.: Non-alcoholic fatty liver disease: The mist gradually clears. J. Hepatology, 2008, 48 , S104–S112.
Day C. P. , 'Non-alcoholic fatty liver disease: The mist gradually clears ' (2008 ) 48 J. Hepatology : S104 -S112 .
Hirose, A., Ono, M., Saibara, T. és mtsai: Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology, 2007, 45 , 1375–1381.
Saibara T. , 'Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis ' (2007 ) 45 Hepatology : 1375 -1381 .
Fehér J., Sulyok S., Várnai K. és mtsai: The effect of a new synthetic dihydroquinoline type antioxidant in experimental atherosclerosis. Lipid Res., 1984, 4 , 20–26.
Várnai K. , 'The effect of a new synthetic dihydroquinoline type antioxidant in experimental atherosclerosis ' (1984 ) 4 Lipid Res. : 20 -26 .
Lindor, K., Kowdley, K., Heathcote, E. és mtsai: Ursodeoxycholic acid for treatment of non alcoholic steatohepatitis: results of a randomized trial. Hepatology, 2004, 39 , 770–778.
Heathcote E. , 'Ursodeoxycholic acid for treatment of non alcoholic steatohepatitis: results of a randomized trial ' (2004 ) 39 Hepatology : 770 -778 .
Dufour, J., Oneta, C., Gonvers, J. és mtsai: Swiss Association for the Study of the Liver: randomized placebo controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol., 2006, 4 , 1537–1543.
Gonvers J. , 'Swiss Association for the Study of the Liver: randomized placebo controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis ' (2006 ) 4 Clin. Gastroenterol. Hepatol. : 1537 -1543 .
Satapathy, S., Sakhuja, P., Malhotra, V. és mtsai: Benefical effects of pentoxyfilline on hepatic steatosis, fibrosis and necroinflammation in patients with non alcoholic steatohepatitis. J. Gastroenterol. Hepatol., 2007, 22 , 634–638.
Malhotra V. , 'Benefical effects of pentoxyfilline on hepatic steatosis, fibrosis and necroinflammation in patients with non alcoholic steatohepatitis ' (2007 ) 22 J. Gastroenterol. Hepatol. : 634 -638 .
Ong, J., Younossi, Z., Reddy, V. és mtsai: Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver. Transpl., 2001, 7 , 797–801.
Reddy V. , 'Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease ' (2001 ) 7 Liver. Transpl. : 797 -801 .